Sonnet BioTherapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Convertible Notes Payable (Details Narrative)

Convertible Notes Payable (Details Narrative) (USD $)	1 Months Ended		3 Months Ended
Convertible Notes Payable (Details Narrative) (USD $)	Mar. 31, 2015	Jan. 31, 2015	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Feb. 28, 2014	Jan. 05, 2015	Dec. 16, 2014	Nov. 19, 2014	Mar. 19, 2014	Aug. 02, 2013
Debt Instrument, Redemption [Line Items]
Proceeds from issuance of debt			$ 2,200,000us-gaap_ProceedsFromConvertibleDebt
Convertible notes payable	2,206,574us-gaap_ConvertibleNotesPayable		2,206,574us-gaap_ConvertibleNotesPayable		1,913,683us-gaap_ConvertibleNotesPayable
Debt instrument, interest rate, stated percentage	11.00%		11.00%			5.00%
Amortized debt discount			474,874	259,442
Conversion of convertible debt amount	250,000	5,000,000
Conversion of debt into shares	168,713	373,333
Derivative liabilities	1,767,300us-gaap_DerivativeLiabilities	125,089us-gaap_DerivativeLiabilities	1,767,300us-gaap_DerivativeLiabilities		1,610,900us-gaap_DerivativeLiabilities
Convertible Promissory Notes [Member]
Debt Instrument, Redemption [Line Items]
Proceeds from issuance of debt			2,150,000
Convertible Promissory Notes One [Member]
Debt Instrument, Redemption [Line Items]
Proceeds from issuance of debt			500,000
Convertible notes payable		1,000,000
Debt instrument, interest rate, stated percentage		8.00%
Percentage of convertible debt to common stock tading price		85.00%
Conversion price per share		$ 1.00
Ceiling price per share		$ 2.00
Issuance of warrants to purchase of common stock		250,000
Common stock, exercisable price per share		$ 2.50
Warrant term		5 years
Conversion of convertible debt amount		500,000
Conversion of debt into shares		373,333
Convertible Promissory Notes One [Member] \| Warrants One [Member]
Debt Instrument, Redemption [Line Items]
Fair value of the embedded conversion feature and the warrants		670,300
Convertible Promissory Notes One [Member] \| Warrants Two [Member]
Debt Instrument, Redemption [Line Items]
Fair value of the embedded conversion feature and the warrants		202,358
Convertible Promissory Notes Two [Member]
Debt Instrument, Redemption [Line Items]
Proceeds from issuance of debt			250,000
Convertible notes payable		150,000
Debt instrument, interest rate, stated percentage		8.00%
Percentage of convertible debt to common stock tading price		85.00%
Conversion price per share		$ 1.00
Ceiling price per share		$ 2.00
Issuance of warrants to purchase of common stock		37,500
Common stock, exercisable price per share		$ 2.50
Warrant term		5 years
Conversion of convertible debt amount		373,333
Conversion of debt into shares		168,713
Convertible Promissory Notes Two [Member] \| Warrants One [Member]
Debt Instrument, Redemption [Line Items]
Fair value of the embedded conversion feature and the warrants		108,600
Convertible Promissory Notes Two [Member] \| Warrants Two [Member]
Debt Instrument, Redemption [Line Items]
Fair value of the embedded conversion feature and the warrants		30,314
Convertible Promissory Notes Two [Member]
Debt Instrument, Redemption [Line Items]
Convertible notes payable	1,000,000		1,000,000
Debt instrument, interest rate, stated percentage	9.00%		9.00%
Conversion price per share	$ 2.00		$ 2.00
Issuance of warrants to purchase of common stock			400,000
Common stock, exercisable price per share	$ 2.50		$ 2.50
Warrant term			5 years
Fair value of the embedded conversion feature and the warrants	315,008		315,008
Amortized debt discount			$ 455,008
Convertible Debt [Member]
Debt Instrument, Redemption [Line Items]
Conversion price per share							$ 1.33	$ 1.3	$ 1.45	$ 3.29	$ 3.73
Percentage of net income received from ownership interest			60.00%
Equity ownerhip interest rate	50.00%		50.00%